এস্তোনিয়া - এস্তোনীয় - Ravimiamet

le vet. beheer b.v. - ketamiin - süstelahus - 100mg 1ml 25ml 1tk; 100mg 1ml 50ml 1tk; 100mg 1ml 10ml 1tk

ইউরোপীয় ইউনিয়ন - এস্তোনীয় - EMA (European Medicines Agency)

accord healthcare s.l.u. - rivaroksabaan - acute coronary syndrome; coronary artery disease; peripheral arterial disease; venous thromboembolism; stroke; atrial fibrillation; pulmonary embolism - antitrombootilised ained - täiskasvanud patsientidel, kellele tehti plaaniline puusa- või põlveliigese asendamise operatsiooni venoosse trombemboolia (vte) ennetamine. ravi süvaveenide tromboos (dvt) ja kopsuarteri emboolia (pe), ning ennetamine korduvate digi-tv ja pe täiskasvanutel. (see section 4. 4 for haemodynamically unstable pe patients. ravi süvaveenide tromboos (dvt) ja kopsuarteri emboolia (pe), ning ennetamine korduvate digi-tv ja pe täiskasvanutel. (see section 4. 4 haemodynamically ebastabiilne pe patsientidel). adultsprevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. ravi süvaveenide tromboos (dvt) ja kopsuarteri emboolia (pe), ning ennetamine korduvate digi-tv ja pe täiskasvanutel. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. rivaroxaban accord, co administered with acetylsalicylic acid (asa) alone or with asa plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers (see sections 4. 3, 4. 4 ja 5. rivaroxaban accord, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. ravi süvaveenide tromboos (dvt) ja kopsuarteri emboolia (pe), ning ennetamine korduvate digi-tv ja pe täiskasvanutel. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

ইউরোপীয় ইউনিয়ন - এস্তোনীয় - EMA (European Medicines Agency)

merck sharp & dohme b.v. - ertugliflozin l-pyroglutamic acid, metformin hydrochloride - suhkurtõbi, tüüp 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - segluromet is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:in patients not adequately controlled on their maximally tolerated dose of metformin alonein patients on their maximally tolerated doses of metformin in addition to other medicinal products for the treatment of diabetesin patients already being treated with the combination of ertugliflozin and metformin as separate tablets.

এস্তোনিয়া - এস্তোনীয় - Ravimiamet

b. braun melsungen ag - propofool - süste-/infusiooniemulsioon - 10mg 1ml 100ml 10tk; 10mg 1ml 10ml 10tk; 10mg 1ml 20ml 10tk; 10mg 1ml 100ml 1tk

ইউরোপীয় ইউনিয়ন - এস্তোনীয় - EMA (European Medicines Agency)

paion deutschland gmbh - remimazolam besilate - teadlik sedatsioon - psühhoeptikumid - remimazolam is indicated in adults for procedural sedation. remimazolam 50 mg is indicated in adults for intravenous induction and maintenance of general anaesthesia.

এস্তোনিয়া - এস্তোনীয় - Ravimiamet

alfasan nederland b.v. - deksmedetomidiin - süstelahus - 0,5mg 1ml 5ml 1tk

ইউরোপীয় ইউনিয়ন - এস্তোনীয় - EMA (European Medicines Agency)

air liquide santé international - hapnik - kõik muud ravitoimingud - horses; dogs; cats - hapniku lisamisel ja kandegaasina inhalatsiooni ajal anesteesia. hapniku lisamine taastumise ajal.

ইউরোপীয় ইউনিয়ন - এস্তোনীয় - EMA (European Medicines Agency)

bayer ag - rivaroksabaan - arthroplasty, replacement; venous thromboembolism - antitrombootilised ained - xarelto, co-manustada atsetüülsalitsüülhape (asa) üksi või koos asa pluss clopidogrel või ticlopidine, on näidustatud ennetamine atherothrombotic sündmuste täiskasvanud patsientidel pärast äge koronaarsündroom (acs) kõrgenenud südame biomarkerite. xarelto, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. täiskasvanud patsientidel, kellele tehti plaaniline puusa- või põlveliigese asendamise operatsiooni venoosse trombemboolia (vte) ennetamine. ravi süvaveenide tromboos (dvt) ja kopsuarteri emboolia (pe), ning ennetamine korduvate digi-tv ja pe täiskasvanutel. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

এস্তোনিয়া - এস্তোনীয় - Ravimiamet

takeda pharma as - nebivolool - tablett - 5mg 20tk; 5mg 56tk; 5mg 14tk; 5mg 100tk; 5mg 120tk; 5mg 28tk; 5mg 60tk; 5mg 30tk; 5mg 7tk; 5mg 10tk

এস্তোনিয়া - এস্তোনীয় - Ravimiamet

b. braun melsungen ag - propofool - süste-/infusiooniemulsioon - 20mg 1ml 50ml 1tk